Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response.
about
Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in micePotentiating cancer immunotherapy using an oncolytic virusProduction of adenovirus vectors and their use as a delivery system for influenza vaccines.Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.Exploring DNA damage responses in human cells with recombinant adenoviral vectors.Adenoviral vector immunity: its implications and circumvention strategies.Adenovirus receptors and their implications in gene deliveryEnhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity.Current strategies and future directions for eluding adenoviral vector immunityEngineering biomaterial systems to enhance viral vector gene delivery.Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.MicroRNA delivery for regenerative medicine.Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.Gene delivery from polymer scaffolds for tissue engineering.Development of nonhuman adenoviruses as vaccine vectors.Strategies to circumvent humoral immunity to adeno-associated viral vectors.Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".Adenoviral vector-based strategies for cancer therapy.Engineered adenovirus serotypes for overcoming anti-vector immunity.Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).Adenovirus-vectored vaccines.Hydrogels for lentiviral gene delivery.Composite alginate microspheres as the next-generation egg-box carriers for biomacromolecules delivery.Adenovirus-triggered innate signalling pathways.Viruses, Artificial Viruses and Virus-Based Structures for Biomedical Applications.Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.Biomaterial-Guided Gene Delivery for Musculoskeletal Tissue Repair.Biomaterial-mediated retroviral gene transfer using self-assembled monolayers.Repression of allo-cell transplant rejection through CIITA ribonuclease P+ hepatocyte.Vaccine Engineering with Dual-Functional Mineral Shell: A Promising Strategy to Overcome Preexisting Immunity.Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.Can myoglobin expression in pancreatic beta cells improve insulin secretion under hypoxia? An exploratory study with transgenic porcine islets.Synthesis and enhanced thermal stability of albumins@alumina: towards injectable sol-gel materials.
P2860
Q21092172-ECB038A3-0E18-43A5-8CBE-57CF0C7DA3D9Q24628810-7A4ECE1E-EC0E-406F-B312-A8BD70D8DD24Q30226988-9A0D6065-6F65-48DE-B6DD-609193090721Q30352927-81E7B93B-4A40-44CE-B265-9651CD360FF1Q33307471-35B9406B-AB4E-4CEF-BAD6-B0043D7FBA61Q33565630-5EFD9304-0E1B-4FAC-AA4D-768CEC733A1FQ33994011-218B1D54-80FF-4DDB-9297-8A6970755B06Q34069571-377D328D-6FC7-4278-ACBE-B3DBC8F9A514Q34585554-DA67901B-2614-48F9-8C97-6B4217445ECCQ35144415-DB51EC59-B7A5-4173-A9B6-B0E1EF9D9DF5Q35624010-010213AE-0D14-43D1-9B22-A841E8836D5FQ35863950-8B0DD6AC-8C42-41F8-9CAB-5A9BBD4BD0A4Q36276187-0DBFDB5E-657C-49D9-A8F9-4061352466F9Q36314939-6C2F7904-AB8E-4F00-A2AC-E43EC7DE8FE8Q36317264-C59EC608-F0EA-44B2-B49E-81A23AE13FF9Q36398678-12A2155D-D524-4FB8-8864-80FC2419EE8BQ36498186-B9DA5FEF-4893-446F-8751-8D41A2962FA1Q37409025-9BEE454C-CDD2-4FB5-BEDB-63A0C3B4A72EQ37567831-2D894809-A865-4DFA-BA0D-CBF5B7D4E43FQ37615161-B0919CCA-7855-4D48-ADC7-56F4ACDF314EQ37689799-9720C449-847F-408D-83A5-D287B5E7D702Q38076509-89ECDBE8-674F-447F-8CAA-D3C90ED5E823Q38104796-9B577FA0-42F7-4001-9468-534B6B594FC9Q38187126-1890FAA5-BC42-4BE1-AFDC-73FC11A6AE43Q38818912-452AF079-D1C3-4451-BB60-C3372A7B11FBQ38848060-55693CB3-52AB-4971-9CCF-43E5B1FDBB7DQ39122705-2159D4E2-EAF6-4D1A-B229-E0BC77FD45E5Q40119114-35A3DC5A-9060-4F13-B22E-284A83DD94ADQ40591525-FC20E9D4-467A-47C6-864F-84D62C258961Q41097174-29D6F0DA-AA11-459A-917B-E214B17DD337Q45872770-A0A95CB3-226A-4FC9-B702-CE65377E3E66Q50675990-AB02A3A0-ADEF-442B-8357-22311DE8817BQ50986730-45DA3D62-DD8B-4E2A-948F-B17921DFB738
P2860
Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Encapsulation of recombinant a ...... ctor-specific immune response.
@ast
Encapsulation of recombinant a ...... ctor-specific immune response.
@en
Encapsulation of recombinant a ...... ctor-specific immune response.
@nl
type
label
Encapsulation of recombinant a ...... ctor-specific immune response.
@ast
Encapsulation of recombinant a ...... ctor-specific immune response.
@en
Encapsulation of recombinant a ...... ctor-specific immune response.
@nl
prefLabel
Encapsulation of recombinant a ...... ctor-specific immune response.
@ast
Encapsulation of recombinant a ...... ctor-specific immune response.
@en
Encapsulation of recombinant a ...... ctor-specific immune response.
@nl
P2093
P2860
P356
P1433
P1476
Encapsulation of recombinant a ...... ctor-specific immune response.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.GT.3301858
P577
2002-12-01T00:00:00Z
P5875
P6179
1041848277